天美传媒

Director of the Blood and Marrow Transplant Center, Roswell Park Cancer Institute Areas of expertise: Bone marrow transplant, leukemia, lymphoma, multiple myeloma, blood cancer, hematologic oncology

Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T鈥檚 and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. 

Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation.  He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market 鈥� one that has transformed the treatment of certain leukemias and lymphomas.

He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor鈥檚 (allogeneic) or a patient鈥檚 own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, 鈥渞educed intensity鈥� (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT.

Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous 鈥済raft-vs-host鈥� effects on normal tissues.

Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra庐) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant 鈥渃onditioning鈥� or as 鈥渕aintenance鈥� to extend remissions after allogeneic transplantation.

As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch鈥檚 clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.

Dr. Alderuccio is a board-certified Hematologist-Oncologist, and specializes in the treatment of patients diagnosed with lymphoma. He also conducts clinical research focused on expanding the treatment repertoire for patients diagnosed with various lymphomas.

Dr. Alderuccio research efforts are geared toward improving and expanding the treatment options available for patients diagnosed with both aggressive and indolent lymphomas. In particular, he is interested in the development of novel, targeted therapies which hinges on the use of genetic sequencing technology. His current research is aimed at identifying clinical characteristics in patients with marginal zone lymphoma in an attempt to distinguish those prone to a worse outcome, as well as a higher risk for transformation to an aggressive lymphoma. Furthermore, he is also involved in studies utilizing molecular imaging in the risk stratification of lymphoma patients, with the goal of developing strategies for individualize care.

Dr Alencar is an Associate Professor of Clinical Medicine and the Associate Chief Medical Officer at University of Miami Sylvester Comprehensive Cancer Center. He is a member of the lymphoma program at Sylvester and the lymphoma committee at the Alliance for Clinical Trials in Oncology with a focus on clinical research of b-cell lymphoid malignancies with special interest in minorities, particularly elderly and Hispanics. His research focuses on the application of novel agents to improve responses and minimize toxicity on the care of elderly patients. As the hematology section lead for the Sylvester鈥檚 Global Oncology Program, Dr Alencar serves as an important bridge to the United States for Latin American hematologists being a constant presence in meetings, lectures, as well as direct patient care through international tumor boards and second opinions. These collaborations have led to a large multinational study evaluating the impact of genetic mutations and ancestry on outcomes of Hispanic patients with blood disorders.

Dr. Moskowitz is an International expert in Lymphoma whose research focuses on Hodgkin Lymphoma, diffuse large B cell lymphoma and mantle cell lymphoma incorporating molecular and radiologic imaging models. Investigational therapy focuses on the use of new drugs including, targeted therapy, checkpoint inhibitors, antibody-drug conjugates and cellular therapy. In addition, as Physician in Chief and Deputy Cancer Center Director at the Sylvester Comprehensive Cancer Center he oversees all oncologic Care focusing on the use of evidence-based medicine, interventional clinical trials and precision medicine to optimize the management of all subtypes of cancer.

Dr. Lakshmi Nayak serves as Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston. She is an Associate Professor of Neurology at Harvard Medical School. She received her medical degree at Grant Medical College in Mumbai, India. She completed her residency at New York Presbyterian Hospital/ Cornell, and fellowship at Memorial Sloan-Kettering Cancer Center in New York. Her research includes development of novel therapies through preclinical and clinical studies for management of primary brain tumors including glioblastoma and primary central nervous system lymphoma, with particular focus on molecular targeted agents and immunotherapeutics, including CAR T-cell therapy.  She leads the international neurologic assessment in neuro-oncology (NANO) effort for evaluation of neurologic function in patients with brain tumors. 

Oncologist Patricia LoRusso, DO, associate director of innovative medicine at Yale Medicine, has expertise in testing new treatments on patient volunteers who have advanced stages of cancer. Her passion is bringing research breakthroughs into the clinic to help patients with different types and stages of cancer.
The clinical trials at Yale Cancer Center offer access to experimental drugs that are sometimes a patient’s last and best hope, says Dr. LoRusso. Therapies that prove successful can advance through the U.S. Food and Drug Administration approval process. “Many of the drugs tested here will help generations of cancer patients,” says Dr. LoRusso. In her career, 14 cancer drugs she has performed clinical trials on, which she refers to as her “children,” have gone on to gain FDA approval.
Dr. LoRusso leads the Phase I clinical trials infusion center at Smilow Cancer Hospital at Yale New Haven. She infuses the center with a warm, team-focused approach that puts patients at the center of care. “We’re improving patients’ lives in Connecticut and beyond,” says Dr. LoRusso.

Gilbert Youssef, MD is Neuro-Oncologist at Dana-Farber Cancer Institute.  He primarily treats patients with brain and spinal cord tumors, including, glioma, meningioma, ependymoma, medulloblastoma, schwannoma, lymphoma, and brain metastases.  He also treats patients who develop neurologic complications from cancer or its treatment.
He is interested in neuroimaging, while focusing on clinical endpoints in clinical trials.  He is also involved in multiple clinical trials that are ongoing at Dana-Farber.

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.




 

Dr. Pongas is a board certified hematologist and oncologist with clinical experience in indolent and aggressive lymphomas. His research interest is the development of cancer therapeutics for B cell lymphomas and viral associated lymphomas. He has done significant laboratory work in Diffuse Large B cell lymphoma elucidating the therapeutic role of inhibiting various PI3K isoforms. He collaborates with clinical scientists to develop novel therapies in lymphomas and with laboratory scientists to study the mechanism of resistance to the therapies and ways to bypass it. With this approach he hopes to develop combinational therapies and increase the cure rates of various lymphomas.

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Institute and the Samuel Durand Professor of Medicine at the University of Rochester Medical Center. He is a driving force behind the operations of Wilmot’s clinical and research programs, leading a team of associate directors who help make decisions surrounding Wilmot’s clinical, research, education, and community outreach missions.
Dr. Friedberg serves as the editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO). He began this five-year term in June 2021. Prior to his editor-in-chief role, he served as associated editor of JCO. He has also served as a reviewer and on editorial boards for a number of medical journals.
Friedberg is a chair of the lymphoma committee in the SWOG group of the NCI National Clinical Trials Network and is an independently R01-funded investigator in the field of lymphoid malignancies.
Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.
His research interests focus on development of novel therapies for patients with lymphoma. He formerly received a Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma. He is currently funded as PI of the ILyAD trial, evaluating patients with follicular lymphoma receiving rituximab with a vitamin D intervention. As chair of SWOG, he is co-leader of the current North American intergroup effort in advanced stage Hodgkin lymphoma. He is also a founding member of the Lymphoma Epidemiology of Outcomes Consortium.

Dr. Matthew Berry joined the faculty at the College of Veterinary Medicine as Assistant Professor last year, but he’s been part of the college since he arrived as a veterinary student in 2013. After completing the DVM program in 2017 he stayed and completed his rotating internship and residency in medical oncology. He is continuing training in a PhD program to expand on his research interests and he enjoys challenging veterinary students to think as a referring veterinarian and discussing how to work with the oncology team to provide the best possible care for the patients they will refer.